Brokerages Set Bausch Health Companies Inc. (NYSE:BHC) Price Target at $7.17

Bausch Health Companies Inc. (NYSE:BHC - Get Free Report) has been assigned a consensus recommendation of "Reduce" from the seven analysts that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation and six have given a hold recommendation to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $7.17.

Several brokerages recently weighed in on BHC. StockNews.com upgraded shares of Bausch Health Companies from a "hold" rating to a "buy" rating in a research report on Thursday. Royal Bank of Canada reduced their price target on Bausch Health Companies from $9.00 to $8.50 and set a "sector perform" rating for the company in a report on Monday, April 7th. Finally, Jefferies Financial Group reissued a "hold" rating and issued a $8.00 target price (down from $12.00) on shares of Bausch Health Companies in a research note on Thursday, February 6th.

Bausch Health Companies Stock Performance

Shares of BHC traded down $0.16 during trading hours on Friday, reaching $5.15. The stock had a trading volume of 965,818 shares, compared to its average volume of 2,693,711. The stock has a market capitalization of $1.90 billion, a PE ratio of -42.95, a PEG ratio of 0.37 and a beta of 0.43. Bausch Health Companies has a 12 month low of $3.96 and a 12 month high of $9.85. The company's 50-day moving average is $6.14 and its two-hundred day moving average is $7.26.

Bausch Health Companies (NYSE:BHC - Get Free Report) last posted its earnings results on Wednesday, February 19th. The company reported $1.21 earnings per share for the quarter, missing analysts' consensus estimates of $1.65 by ($0.44). Bausch Health Companies had a negative net margin of 0.48% and a negative return on equity of 577.82%. The company had revenue of $2.56 billion during the quarter, compared to the consensus estimate of $2.51 billion. Equities analysts anticipate that Bausch Health Companies will post 4.41 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Bausch Health Companies

Several large investors have recently bought and sold shares of the stock. Mountain Hill Investment Partners Corp. bought a new position in shares of Bausch Health Companies in the fourth quarter worth $56,000. Wealthquest Corp bought a new position in Bausch Health Companies during the 1st quarter valued at approximately $58,000. Bank of Nova Scotia bought a new position in shares of Bausch Health Companies during the fourth quarter valued at $83,000. One68 Global Capital LLC bought a new position in Bausch Health Companies in the 4th quarter valued at approximately $90,000. Finally, Balyasny Asset Management L.P. bought a new stake in shares of Bausch Health Companies in the fourth quarter worth approximately $97,000. 78.65% of the stock is currently owned by institutional investors.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.